Difference between revisions of "CTSC:multicenter042110"
From NAMIC Wiki
| Line 30: | Line 30: | ||
* Validation is key, consistency of results is crucial. Reproducibility across sites and across vendors must be achieved. | * Validation is key, consistency of results is crucial. Reproducibility across sites and across vendors must be achieved. | ||
* Jeff suggested to look at some of the existing, already funded multicenter trial and see if we could help them wirk on a better reproducibility across site. He cited the example of neuro-oncology trials with DCE-MRI. So far the acquisitions are not standardized across institutions. At DFCI they are now testing the sequences used by Greg Sorensen at MGH. | * Jeff suggested to look at some of the existing, already funded multicenter trial and see if we could help them wirk on a better reproducibility across site. He cited the example of neuro-oncology trials with DCE-MRI. So far the acquisitions are not standardized across institutions. At DFCI they are now testing the sequences used by Greg Sorensen at MGH. | ||
| − | * Simon | + | * Simon agreed, the same problems exist in pediatric neuro-oncology. He suggested to do a simulation to be able to show that by using protocols that are not standardized one gets different results. |
| + | * | ||
Revision as of 04:01, 18 May 2010
Home < CTSC:multicenter042110Back to Collaboration:Harvard_CTSC
Agenda
- Definition of goals for this new subgroup
- Learn from existing multicenter trials
Multicenter Clinical Trail Working group Meeting Minutes April 21, 2010
In attendance:
- Valerie Humblet
- Bob Lenkinski
- Clare Tempany
- Charles Guttmann
- Simon Warfield
- Jeff Yap
- Neil Rofsky
1. Goals
- The main goal of this group is to set up a imaging trial across Harvard. It could be a virtual trial (no need for funding) or a real trial. Several modalities must be considered.
- The goal is to start with a simple example and then go for more complicated examples.
- Being able to do a successful cross-Harvard imaging trial is be very good with the perspective of the CTSA grant renewal.
2. Discussion
- Validation is key, consistency of results is crucial. Reproducibility across sites and across vendors must be achieved.
- Jeff suggested to look at some of the existing, already funded multicenter trial and see if we could help them wirk on a better reproducibility across site. He cited the example of neuro-oncology trials with DCE-MRI. So far the acquisitions are not standardized across institutions. At DFCI they are now testing the sequences used by Greg Sorensen at MGH.
- Simon agreed, the same problems exist in pediatric neuro-oncology. He suggested to do a simulation to be able to show that by using protocols that are not standardized one gets different results.
